EUVIMEDEUVIMED entdecken
Crossref

Midterm outcomes after TAVR or SAVR in low-risk patients with severe aortic stenosis in the real clinical practice in Japan

Kotaro Takahashi, Yasuaki Takeji, Tomohiko Taniguchi, Takeshi Morimoto, Shinichi Shirai, Takeshi Kitai, Hiroyuki Tabata, Nobuhisa Ohno, Ryosuke Murai, Kohei Osakada, Koichiro Murata, Masanao Nakai und 32 weitere

Cardiovascular Intervention and Therapeutics · 2026

DOI: 10.1007/s12928-026-01301-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiovascular Intervention and Therapeutics, 2026. Verfasst von Kotaro Takahashi und 43 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Shizuoka General Hospital, Shizuoka, Japan. Hauptthemen laut MEDLINE: Aortic Valve Stenosis, Transcatheter Aortic Valve Replacement, Heart Valve Prosthesis Implantation. Die Arbeit nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The clinical trials in low risk patients have clearly demonstrated clinical outcomes of transcatheter aortic-valve replacement (TAVR) comparable to those of surgical aortic-valve replacement (SAVR) in patients with severe aortic stenosis (AS). However, data are lacking on the appropriate treatment selection for patients with severe AS and low surgical risk in Japanese routine clinical practice. Among 3369 patients enrolled in the CURRENT AS Registry-2 between April 2018 and December 2020, the current study population include 826 patients with low Society of Thoracic Surgeons (STS) score and not on hemodialysis who actually underwent TAVR (439 patients) or SAVR (387 patients). After propensity score matching, there remained 162 patients in each group. The primary outcome was a composite of all-cause death, disabling stroke, or heart failure hospitalization. The cumulative 3-year incidence of the primary outcome was not significantly different between the TAVR and SAVR groups (19.5% and 17.4%, P = 0.82). Even after adjusting for age and institution, there was no excess risk of TAVR relative to SAVR for the primary outcome (adjusted HR: 1.05, 95% CI: 0.50-2.20, P = 0.91). In low-risk patients with severe AS, TAVR compared to SAVR was associated with comparable clinical outcomes for a composite of all-cause death, disabling stroke and heart failure hospitalization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aortic Valve StenosisTranscatheter Aortic Valve ReplacementHeart Valve Prosthesis ImplantationHumansFemaleJapanMaleAged, 80 and overRegistriesAgedSeverity of Illness IndexTreatment OutcomeRisk FactorsPostoperative ComplicationsRisk AssessmentStroke

Stichwörter der Autor:innen

Low-riskSAVRTAVR

Autor:innen und Institutionen

  • Department of Cardiology, Shizuoka General Hospital, Shizuoka, Japan.
  • Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.
  • Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe, Japan.
  • Department of Data Science, Hyogo Medical University, Nishinomiya, Japan.
  • Division of Cardiology, Kokura Memorial Hospital, Kitakyushu, Japan.

Zitieren

APA

Takahashi, K., Takeji, Y., Taniguchi, T., Morimoto, T., Shirai, S., Kitai, T., Tabata, H., Ohno, N., Murai, R., Osakada, K., Murata, K., Nakai, M., Tsuneyoshi, H., Tada, T., Amano, M., Watanabe, S., Shiomi, H., Watanabe, H., Yoshikawa, Y., …, & Current as Registry-2 Investigators (2026). Midterm outcomes after TAVR or SAVR in low-risk patients with severe aortic stenosis in the real clinical practice in Japan. Cardiovascular Intervention and Therapeutics. https://doi.org/10.1007/s12928-026-01301-2

Vancouver

Takahashi K, Takeji Y, Taniguchi T, Morimoto T, Shirai S, Kitai T, et al. Midterm outcomes after TAVR or SAVR in low-risk patients with severe aortic stenosis in the real clinical practice in Japan. Cardiovascular Intervention and Therapeutics. 2026. doi:10.1007/s12928-026-01301-2

BibTeX
@article{Takahashi2026,
  author = {Takahashi, Kotaro and Takeji, Yasuaki and Taniguchi, Tomohiko and Morimoto, Takeshi and Shirai, Shinichi and Kitai, Takeshi and Tabata, Hiroyuki and Ohno, Nobuhisa and Murai, Ryosuke and Osakada, Kohei and Murata, Koichiro and Nakai, Masanao and Tsuneyoshi, Hiroshi and Tada, Tomohisa and Amano, Masashi and Watanabe, Shin and Shiomi, Hiroki and Watanabe, Hirotoshi and Yoshikawa, Yusuke and Nishikawa, Ryusuke and Obayashi, Yuki and Yamamoto, Ko and Toyofuku, Mamoru and Tatsushima, Shojiro and Kanamori, Norio and Miyake, Makoto and Nakayama, Hiroyuki and Nagao, Kazuya and Izuhara, Masayasu and Nakatsuma, Kenji and Inoko, Moriaki and Fujita, Takanari and Kimura, Masahiro and Ishii, Mitsuru and Usami, Shunsuke and Nakazeki, Fumiko and Togi, Kiyonori and Inuzuka, Yasutaka and Ando, Kenji and Komiya, Tatsuhiko and Ono, Koh and Minatoya, Kenji and Kimura, Takeshi and Current as Registry-2 Investigators, Current as Registry-2 Investigators},
  title = {Midterm outcomes after TAVR or SAVR in low-risk patients with severe aortic stenosis in the real clinical practice in Japan},
  journal = {Cardiovascular Intervention and Therapeutics},
  year = {2026},
  doi = {10.1007/s12928-026-01301-2}
}
Kostenlos starten →